請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68806
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林芳如(Fang-Ju Lin) | |
dc.contributor.author | Yueh-Hsin Wang | en |
dc.contributor.author | 王悅心 | zh_TW |
dc.date.accessioned | 2021-06-17T02:36:19Z | - |
dc.date.available | 2022-09-14 | |
dc.date.copyright | 2017-09-14 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-08-17 | |
dc.identifier.citation | 1. Schmitt J, Duray G, Gersh BJ and Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;30:1038-45.
2. McDonald M, Desai N, You C-H and Haywood LJ. Influence of atrial fibrillation on acute myocardial infarction. Health. 2014;06:86-89. 3. Violi F, Soliman EZ, Pignatelli P and Pastori D. Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. 2016;5:e003347. 4. Tsai C-F, Thomas B and Sudlow CLM. Epidemiology of stroke and its subtypes in Chinese vs white populations: A systematic review. Neurology. 2013;81:264-272. 5. Shen AY, Yao JF, Brar SS, Jorgensen MB and Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. Journal of the American College of Cardiology. 2007;50:309-15. 6. Sabir I, Khavandi K, Brownrigg J and Camm AJ. Oral anticoagulants for Asian patients with atrial fibrillation. Nat Rev Cardiol. 2014;11:290-303. 7. Spinler SA and Denus Sd. Acute coronary syndrome. Pharmacotherapy: a Pathophysiological Approach. 9 ed. New York, USA: McGraw-Hill Professional Publishing; 2014: 467-527. 8. 衛生福利部. 青壯救心7行動. 2015. 9. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D and Turner MB. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-e245. 10. Chiang FT, Shyu KG, Wu CJ, Mar GY, Hou CJ, Li AH, Wen MS, Lai WT, Lin SJ, Kuo CT, Kuo C, Li YH, Hwang JJ and Investigators ACSFSR. Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry. J Formos Med Assoc. 2014;113:794-802. 11. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Jr., Ganiats TG, Holmes DR, Jr., Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ, American College of C, American Heart Association Task Force on Practice G, Society for Cardiovascular A, Interventions, Society of Thoracic S and American Association for Clinical C. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2014;64:e139-228. 12. Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ and Zhao DX. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Circulation. 2012. 13. American College of Emergency P, Society for Cardiovascular A, Interventions, O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Jr., Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG and Yancy CW. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2013;61:e78-140. 14. Smith SC, Jr., Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH and Taubert KA. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458-73. 15. Sanoski CA and Bauman JL. Pharmacotherapy: a Pathophysiological Approach The Arrhythmias 9ed. New York, USA: McGraw-Hill Professional Publishing; 2014: 528-612. 16. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr., Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW and American College of Cardiology/American Heart Association Task Force on Practice G. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology. 2014;64:e1-76. 17. Chien KL, Su TC, Hsu HC, Chang WT, Chen PC, Chen MF and Lee YT. Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. Int J Cardiol. 2010;139:173-80. 18. European Heart Rhythm A, European Association for Cardio-Thoracic S, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P and Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-429. 19. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL and Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-2962. 20. Venkitachalam L, Kip KE, Selzer F, Wilensky RL, Slater J, Mulukutla SR, Marroquin OC, Block PC, Williams DO and Kelsey SF. Twenty-year evolution of percutaneous coronary intervention and its impact on clinical outcomes: a report from the National Heart, Lung, and Blood Institute-sponsored, multicenter 1985-1986 PTCA and 1997-2006 Dynamic Registries. Circ Cardiovasc Interv. 2009;2:6-13. 21. Lu TH, Huang YT, Lee JC, Yang LT, Liang FW, Yin WH and Kawachi I. Characteristics of Early and Late Adopting Hospitals Providing Percutaneous Coronary Intervention in Taiwan. J Am Heart Assoc. 2015;4. 22. Smith SC, Jr., Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, Kuntz RE, Popma JJ, Schaff HV, Williams DO, Gibbons RJ, Alpert JP, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russell RO and Smith SC, Jr. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation. 2001;103:3019-41. 23. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK and Ting HH. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574-651. 24. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK and Smith SC, Jr. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2016;68:1082-115. 25. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P and Advisors. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J. 2016. 26. Dewilde WJM, Oirbans T, Verheugt FWA, Kelder JC, De Smet BJGL, Herrman J-P, Adriaenssens T, Vrolix M, Heestermans AACM, Vis MM, Tijsen JGP, van 't Hof AW and ten Berg JM. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. The Lancet. 2013;381:1107-1115. 27. Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D, Hoppmann P, Schneider S, Fusaro M, Ott I, Kristensen SD, Ibrahim T, Massberg S, Schunkert H, Laugwitz KL, Kastrati A and Sarafoff N. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. Journal of the American College of Cardiology. 2015;65:1619-29. 28. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED and Fox KA. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016;375:2423-2434. 29. Barbieri L, Verdoia M, Schaffer A, Suryapranata H and De Luca G. Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies. Cardiovasc Drugs Ther. 2016;30:611-622. 30. Liu J, Fan M, Zhao J, Zhao B, Zhang C, Liu C and Dong Y. Efficacy and safety of antithrombotic regimens after coronary intervention in patients on oral anticoagulation: Traditional and Bayesian meta-analysis of clinical trials. Int J Cardiol. 2016;205:89-96. 31. Zhao HJ, Zheng ZT, Wang ZH, Li SH, Zhang Y, Zhong M and Zhang W. 'Triple therapy' rather than 'triple threat': a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest. 2011;139:260-70. 32. D'Ascenzo F, Taha S, Moretti C, Omede P, Grossomarra W, Persson J, Lamberts M, Dewilde W, Rubboli A, Fernandez S, Cerrato E, Meynet I, Ballocca F, Barbero U, Quadri G, Giordana F, Conrotto F, Capodanno D, DiNicolantonio J, Bangalore S, Reed M, Meier P, Zoccai G and Gaita F. Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2015;115:1185-93. 33. Chen CF, Chen B, Zhu J and Xu YZ. Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulant treatment. A meta-analysis. Herz. 2015;40:1070-83. 34. Gao F, Zhou YJ, Wang ZJ, Shen H, Liu XL, Nie B, Yan ZX, Yang SW, Jia DA and Yu M. Comparison of Different Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation. Circulation Journal. 2010;74:701-708. 35. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, Kober L, Torp-Pedersen C, Gislason GH and Hansen ML. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126:1185-93. 36. Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, Christensen CB, Lip GY, Kober L, Torp-Pedersen C and Hansen ML. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. Journal of the American College of Cardiology. 2013;62:981-9. 37. Fosbol EL, Wang TY, Li S, Piccini J, Lopes RD, Mills RM, Klaskala W, Thomas L, Roe MT and Peterson ED. Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. American heart journal. 2013;166:864-70. 38. Ho KW, Ivanov J, Freixa X, Overgaard CB, Osten MD, Ing D, Horlick E, Mackie K, Seidelin PH and Dzavik V. Antithrombotic therapy after coronary stenting in patients with nonvalvular atrial fibrillation. Can J Cardiol. 2013;29:213-8. 39. Rubboli A, Schlitt A, Kiviniemi T, Biancari F, Karjalainen PP, Valencia J, Laine M, Kirchhof P, Niemela M, Vikman S, Lip GY, Airaksinen KE and Group AS. One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry. Clin Cardiol. 2014;37:357-64. 40. Mennuni MG, Halperin JL, Bansilal S, Schoos MM, Theodoropoulos KN, Meelu OA, Sartori S, Giacoppo D, Bernelli C, Moreno PR, Krishnan P, Baber U, Lucarelli C, Dangas GD, Sharma SK, Kini AS, Tamburino C, Chieffo A, Colombo A, Presbitero P and Mehran R. Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). Am J Cardiol. 2015;116:37-42. 41. Sambola A, Mutuberria M, Garcia Del Blanco B, Alonso A, Barrabes JA, Bueno H, Alfonso F, Cequier A, Zueco J, Rodriguez-Leor O, Tornos P and Garcia-Dorado D. Impact of Triple Therapy in Elderly Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. PLoS One. 2016;11:e0147245. 42. Sambola A, Ferreira-Gonzalez I, Angel J, Alfonso F, Maristany J, Rodriguez O, Bueno H, Lopez-Minguez JR, Zueco J, Fernandez-Aviles F, San Roman A, Prendergast B, Mainar V, Garcia-Dorado D and Tornos P. Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study. Heart. 2009;95:1483-8. 43. Kawai H, Watanabe E, Yamamoto M, Harigaya H, Sano K, Takatsu H, Muramatsu T, Naruse H, Sobue Y, Motoyama S, Sarai M, Takahashi H, Arakawa T, Kan S, Sugiura A, Murohara T and Ozaki Y. Major bleeding complications related to combined antithrombotic therapy in atrial fibrillation patients 12 months after coronary artery stenting. J Cardiol. 2015;65:197-202. 44. Suh SY, Kang WC, Oh PC, Choi H, Moon CI, Lee K, Han SH, Ahn T, Choi IS and Shin EK. Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation. Heart Vessels. 2014;29:578-83. 45. Kang DO, Yu CW, Kim HD, Cho JY, Joo HJ, Choi RK, Park JS, Lee HJ, Kim JS, Park JH, Hong SJ and Lim DS. Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation. Coron Artery Dis. 2015;26:372-80. 46. Gibbs CR and Lip GYH. Do we still need dipyridamole? British Journal of Clinical Pharmacology. 1998;45:323-328. 47. Lund JL, Richardson DB and Stürmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Current epidemiology reports. 2015;2:221-228. 48. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG, Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D, Document R, Storey RF, Bueno H, Collet JP, Fauchier L, Halvorsen S, Lettino M, Morais J, Mueller C, Potpara TS, Rasmussen LH, Rubboli A, Tamargo J, Valgimigli M and Zamorano JL. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35:3155-79. 49. Carrero JJ, de Jager DJ, Verduijn M, Ravani P, De Meester J, Heaf JG, Finne P, Hoitsma AJ, Pascual J, Jarraya F, Reisaeter AV, Collart F, Dekker FW and Jager KJ. Cardiovascular and noncardiovascular mortality among men and women starting dialysis. Clin J Am Soc Nephrol. 2011;6:1722-30. 50. Clark MA, Bakhai A, Lacey MJ, Pelletier EM and Cohen DJ. Clinical and economic outcomes of percutaneous coronary interventions in the elderly: an analysis of medicare claims data. Circulation. 2004;110:259-64. 51. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG and White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736-47. 52. Sionova M, Blasko P, Jirous S, Vindis D, Rokyta R, Posch L and Motovska Z. Number of severe bleeding complications according to classification used: Is unified classification of bleeding complications really necessary? Cardiol J. 2015;22:665-74. 53. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ and Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-100. 54. Chan PH, Li WH, Hai JJ, Chan EW, Wong IC, Tse HF, Lip GY and Siu CW. Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation. Can J Cardiol. 2016;32:1247 e23-1247 e28. 55. 林欣儀, 陳以雯, 康皓程, 吳宜真, 朱蓁蓁, 林慧玲, 沈麗娟 and 黃織芬. Warfarin在亞洲族群之治療目標準則. 臺灣臨床藥學雜誌. 2015;23:189-202. 56. Cheung CM, Tsoi TH and Huang CY. The lowest effective intensity of prophylactic anticoagulation for patients with atrial fibrillation. Cerebrovascular diseases (Basel, Switzerland). 2005;20:114-9. 57. Rosendaal FR, Cannegieter SC, van der Meer FJ and Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236-9. 58. Schein JR, White CM, Nelson WW, Kluger J, Mearns ES and Coleman CI. Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thrombosis Journal. 2016;14:14. 59. Jorgensen NW, Sibley CT and McClelland RL. Using imputed pre-treatment cholesterol in a propensity score model to reduce confounding by indication: results from the multi-ethnic study of atherosclerosis. BMC Medical Research Methodology. 2013;13:81-81. 60. Eulenburg C, Suling A, Neuser P, Reuss A, Canzler U, Fehm T, Luyten A, Hellriegel M, Woelber L and Mahner S. Propensity Scoring after Multiple Imputation in a Retrospective Study on Adjuvant Radiation Therapy in Lymph-Node Positive Vulvar Cancer. PLoS One. 2016;11:e0165705. 61. Sturmer T, Wyss R, Glynn RJ and Brookhart MA. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med. 2014;275:570-80. 62. Naimi AI, Moodie EE, Auger N and Kaufman JS. Constructing inverse probability weights for continuous exposures: a comparison of methods. Epidemiology (Cambridge, Mass). 2014;25:292-9. 63. Xu S, Ross C, Raebel MA, Shetterly S, Blanchette C and Smith D. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2010;13:273-277. 64. Austin PC. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research. Communications in Statistics - Simulation and Computation. 2009;38:1228-1234. 65. Brown HK, Ray JG, Wilton AS, Lunsky Y, Gomes T and Vigod SN. Association Between Serotonergic Antidepressant Use During Pregnancy and Autism Spectrum Disorder in Children. Jama. 2017;317:1544-1552. 66. Lin LPY-J. Antithrombotic treatment before stroke onset and stroke severity in patients with atrial fibrillation and first-ever ischemic stroke: An observational study. Neurology Asia. 2010;15:11-17. 67. Lin LJ, Cheng MH, Lee CH, Wung DC, Cheng CL and Kao Yang YH. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation--a nationwide descriptive study in Taiwan. Clinical therapeutics. 2008;30:1726-36. 68. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma C, Zint K, Elsaesser A, Bartels DB, Lip GY and Investigators G-A. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. Am J Med. 2015;128:1306-13 e1. 69. Chiang CE, Wu TJ, Ueng KC, Chao TF, Chang KC, Wang CC, Lin YJ, Yin WH, Kuo JY, Lin WS, Tsai CT, Liu YB, Lee KT, Lin LJ, Lin LY, Wang KL, Chen YJ, Chen MC, Cheng CC, Wen MS, Chen WJ, Chen JH, Lai WT, Chiou CW, Lin JL, Yeh SJ and Chen SA. 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. J Formos Med Assoc. 2016;115:893-952. 70. Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y, Fukuyama T, Doi Y, Mochizuki S, Izumi T, Takekoshi N, Yoshida K, Hiramori K, Origasa H, Uchiyama S, Matsumoto M, Yamaguchi T, Hori M and Japan Atrial Fibrillation Stroke Trial G. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2006;37:447-51. 71. Sambola A, Mutuberria M, Garcia Del Blanco B, Alonso A, Barrabes JA, Alfonso F, Bueno H, Cequier A, Zueco J, Rodriguez-Leor O, Bosch E, Tornos P and Garcia-Dorado D. Effects of Triple Therapy in Patients With Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Regarding Thromboembolic Risk Stratification. Circ J. 2016;80:354-62. 72. Greenland S, Schwartzbaum JA and Finkle WD. Problems due to small samples and sparse data in conditional logistic regression analysis. American journal of epidemiology. 2000;151:531-9. 73. Austin PC and Steyerberg EW. The number of subjects per variable required in linear regression analyses. Journal of clinical epidemiology. 2015;68:627-36. 74. Vittinghoff E and McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. American journal of epidemiology. 2007;165:710-8. 75. Takarada K, Sato M, Goto M, Saito A, Ikeda Y, Fujita S, Fuse K, Takahashi M, Oguro T, Matsushita H, Kitazawa H, Okabe M, Abe H, Toba K, Yamashina A and Aizawa Y. Long-term PT-INR levels and the clinical events in the patients with non-valvular atrial fibrillation: A special reference to low-intensity warfarin therapy. Journal of Cardiology. 2014;64:127-132. 76. Shin H-W, Kim Y-N, Bae H-J, Lee H-M, Cho H-O, Cho Y-K, Park H-S, Yoon H-J, Kim H, Nam C-W, Hur S-H, Kim K-B, Lee Y-S and Investigator K. Trends in Oral Anticoagulation Therapy Among Korean Patients With Atrial Fibrillation: The KORean Atrial Fibrillation Investigation. Korean Circulation Journal. 2012;42:113-117. 77. You JHS, Chan FWH, Wong RSM and Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? British Journal of Clinical Pharmacology. 2005;59:582-587. 78. Nelson WW, Desai S, Damaraju CV, Lu L, Fields LE, Wildgoose P and Schein JR. International Normalized Ratio Stability in Warfarin-Experienced Patients with Nonvalvular Atrial Fibrillation. American Journal of Cardiovascular Drugs. 2015;15:205-211. 79. Nelson WW, Desai S and Damaraju CV. International normalized ratio stability in warfarin-experiences patients with nonvalvular atrial fibrillation. Am J Cardiovasc Drugs. 2015;15. 80. Warkentin AE, Donadini MP, Spencer FA, Lim W and Crowther M. Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis. J Thromb Haemost. 2012;10:512-20. 81. Delhaye C, Wakabayashi K, Maluenda G, Belle L, Ben-Dor I, Gonzalez MA, Gaglia MA, Jr., Torguson R, Xue Z, Suddath WO, Satler LF, Kent KM, Lindsay J, Pichard AD and Waksman R. Body mass index and bleeding complications after percutaneous coronary intervention: does bivalirudin make a difference? American heart journal. 2010;159:1139-46. 82. Amundson DE, Djurkovic S and Matwiyoff GN. The obesity paradox. Critical care clinics. 2010;26:583-96. 83. Akin I and Nienaber CA. “Obesity paradox” in coronary artery disease. World Journal of Cardiology. 2015;7:603-608. 84. Lip GY, Nieuwlaat R, Pisters R, Lane DA and Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-72. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68806 | - |
dc.description.abstract | 研究背景
中風的預防是面對心房顫動病人時最重要的議題,目前口服抗凝血藥品(oral anticoagulant)為最有效的預防策略。然而,多數病人可能同時有冠狀動脈疾病的共病症,若發生急性冠心症或接受經皮冠狀動脈介入治療術後,則需使用雙重抗血小板藥品來預防心肌梗塞或支架栓塞的發生。此類病人在同時有使用口服抗凝血藥物及雙重抗血小板藥物的適應症之下,如何平衡栓塞與出血的風險以決定抗血栓藥品的使用一直是臨床上的一大難題。目前多數研究的結果並不一致,且僅有少數研究目標族群以亞洲人為主,過去文獻顯示亞洲人相較於高加索人種有較高的顱內出血傾向,因此亟需以實證資料以確認如何給予有效且具安全性的抗血栓藥物組合。 研究目的 欲了解臺灣心房顫動病人在急性冠心症或經皮冠狀動脈介入治療術後抗血栓藥物使用模式,並比較不同療法之間的療效及安全性。 研究方法 本研究為一回溯性世代研究,利用臺大醫院整合型資料庫納入在2008/1/1至2016/4/1間發生急性冠心症或接受經皮冠狀動脈介入治療術的心房顫動病人,以出院所使用的抗血栓藥物組合做為研究分組,分別為雙重抗血小板藥物、三重抗血栓藥物、雙重抗血栓藥物、單一抗血小板藥物及單一抗凝血藥物組別,以傾向分數(propensity score)及治療權重倒數機率(inverse probability of treatment weighting, IPTW)方法校正組間的基線差異後,進一步以Cox比例風險模式及實際治療分析(as-treated)方式分析各組在用藥期間發生主要不良心腦血管事件(major adverse cardiac and cerebrovascular event, MACCE)及出血事件的差異,並進行敏感性分析。 研究結果 本研究共納入719位發生急性冠心症或接受經皮冠狀動脈介入治療術的心房顫動病人,其入院前抗血栓藥物的使用以抗血小板藥物為主,出院後則以雙重抗血小板藥物為最常使用的抗血栓藥物組合(53.3%),其次為單一抗血小板藥物(23.9%)、三重抗血栓藥物(11.1%)、雙重抗血栓藥物(9.6%)及單一抗凝血藥物(2.1%)。由於樣本數限制,我們僅比較雙重抗血小板藥物、三重抗血栓藥物、雙重抗血栓藥物以及單一抗小板藥物組。各組在主要不良心腦血管事件的追蹤時間中位數分別為133天、31天、280天及149天,各組出血事件的追蹤時間中位數則大致與不良心腦血管事件的追蹤時間中位數相同。整體來說,多數事件發生於出院後六個月內,不良心腦血管事件發生率在本研究為11.4每100人年,而任何出血事件的發生率則為25.9每100人年。在主要不良心腦血管事件的比較上,各組與雙重抗血小板藥物相較無顯著差異,而在出血事件的比較中,雙重抗血栓藥物相較於雙重抗血小板藥物在任何出血上有較低的風險(aHR, 0.20 [95% CI, 0.06-0.75])。 結論 在心房顫動且發生急性冠心症或接受經皮冠狀動脈介入治療術的病人中,以雙重抗血小板藥物為最常使用的抗血栓藥物組合。此外,各組合在療效方面並無顯著差異,在安全性方面則以雙重抗血小板相較於雙重抗血栓藥物可能有較高的出血風險。惟本研究受限於樣本數較小,仍需要未來較大型的研究證實此發現。 | zh_TW |
dc.description.abstract | Background/ Objective
Stroke prevention is fundamental in the management of atrial fibrillation (AF), and oral anticoagulant (OAC) is the most effective prevention strategy. However, some of AF patients are comorbid with coronary artery disease and might present with acute coronary syndrome (ACS) or receive percutaneous coronary intervention (PCI). Dual antiplatelet therapy (DAPT) is the recommended antithrombotic regimen to prevent myocardial infarction or stent thrombosis after ACS or PCI. Whether to use triple therapy (OAC plus DAPT) to prevent thrombotic events in these patients is controversial due to possibly excessive bleedings. There remains insufficient evidence to determine the optimal antithrombotic strategy, especially in the Asian population. This study aimed to examine the real-world treatment patterns of antithrombotic use among these patients and compare the effectiveness and safety of different antithrombotic regimens. Methods A retrospective cohort study was conducted at the National Taiwan University Hospital (NTUH). AF patients undergoing a new ACS or PCI during 2006/1/1-2016/4/1 were enrolled. Antithrombotic regimens were classified into DAPT (the reference group), triple therapy (TT), dual therapy (DT), single antiplatelet therapy (SAPT), and single oral anticoagulant (SOAC). Outcomes of interest included major adverse cardiac and cerebrovascular event (MACCE) and any or major bleeding defined by the PLATO criteria. Propensity score and inverse probability of treatment weighting (IPTW) were used to balance the baseline characteristics among comparison groups. The treatment effect was estimated using Cox proportional hazards model with as-treated approach. A series of sensitivity analyses were also conducted. Results In this study, a total of 719 AF patients presenting with ACS or PCI were included. The use of oral anticoagulant was relatively low at baseline. At the discharge from the index hospitalization for ACS or PCI, DAPT was the most common antithrombotic therapy (53.3%), followed by SAPT (23.9%), TT (11.1%), DT (9.6%), and SOAC (2.1%). Due to the sample size limitation, we only compared TT, DT, and SAPT to DAPT. The median follow-up for MACCE was 133 days in the DAPT group, 31 days in the TT group, 280 days in the DT group, and 149 days in the SAPT group. The median follow-up duration for any bleeding was similar to that for MACCE, but slightly shorter. Most MACCEs and bleeding events were within six months after index hospitalization. The overall incidence rate for MACCE was 11.4 per 100 person-years in the included patients, and 25.9 for any bleeding. No significant difference in MACCE was found among the different antithrombotic regimens. DT, compared to DAPT, was associated with a lower risk of any bleeding (aHR, 0.20 [95% CI, 0.06-0.75]) in the main analysis. Conclusions In AF patients presenting with ACS or PCI, DAPT was the most commonly prescribed antithrombotic regimen for cardio-cerebrovascular disease prevention. Effectiveness outcomes were comparable across different antithrombotic strategies, but the sample size was relatively limited. The increased bleeding risk with DAPT compared with DT warrants further investigation. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T02:36:19Z (GMT). No. of bitstreams: 1 ntu-106-R04451010-1.pdf: 3171237 bytes, checksum: b91393398997355ced1b020f69bb4484 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 致謝 I
中文摘要 II ABSTRACT IV CONTENTS VI LIST OF FIGURES VIII LIST OF TABLES IX LIST OF ABBREVIATIONS XI CHAPTER 1 INTRODUCTION 1 Section 1 Overview 1 Section 2 Study Objectives 2 CHAPTER 2 LITERATURE REVIEW 3 Section 1 Acute Coronary Syndrome 3 Section 2 Atrial Fibrillation 8 Section 3 Percutaneous Coronary Intervention (PCI) 11 Section 4 Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome or Percutaneous Coronary Intervention 14 CHAPTER 3 METHODS 19 Section 1 Data Source 19 Section 2 Study Design 20 Section 3 Statistical Analysis 26 CHAPTER 4 RESULTS 29 Section 1 Patient Characteristics 29 Section 2 Antithrombotic Treatment Patterns 31 Section 3 Effectiveness and Safety Outcomes 32 CHAPTER 5 DISCUSSION 38 Section 1 Patient Characteristics 38 Section 2 Antithrombotic Treatment Patterns 40 Section 3 Effectiveness and Safety Outcomes 42 Section 4 Strengths and Limitations 46 CHAPTER 6 CONCLUSIONS 48 REFERENCES 49 FIGURES 64 TABLES 70 APPENDIX 97 | |
dc.language.iso | en | |
dc.title | 抗血栓藥物使用於發生急性冠心症或施行經皮冠狀動脈介入術後且併有心房顫動病人之用藥模式研究與療效、安全性評估 | zh_TW |
dc.title | Treatment Patterns and Outcomes Study of Antithrombotic Use in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome or Percutaneous Coronary Intervention | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 高憲立(Hsien-Li Kao),王繼娟,林欣儀 | |
dc.subject.keyword | 抗血栓藥物,心房顫動,急性冠心症,經皮冠狀動脈介入治療術, | zh_TW |
dc.subject.keyword | Antithrombotic use,atrial fibrillation,acute coronary syndrome,percutaneous coronary intervention, | en |
dc.relation.page | 100 | |
dc.identifier.doi | 10.6342/NTU201703850 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-08-17 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 3.1 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。